Special Issues

Special Issue Title: Radiotherapy for Gynecological Oncology

· Print Special Issue Flyer

· Deadline for manuscript submissions:  30 September 2021

Special Issue Editor

Guest Editor

Prof Dr. Cem Onal

Baskent University Faculty of Medicine, Adana Dr. Turgut Noyan Research and Treatment Centre, Department of Radiation Oncology, Adana, Turkey

Website | E-Mail

Interests: Radiotherapy; Gynecologic Oncology

Special Issue Information

Dear Colleagues,

Radiation therapy is an essential component of gynecological malignancies, either used as definitive treatment or as adjuvant postoperative treatment. The role of radiotherapy in gynecological cancer is important, because gynecologic cancers were among the first malignancies treated with ionizing radiation, more than a century ago. Both external radiotherapy and intracavitary or interstitial brachytherapy are frequently used for patients with gynecological malignancies. Although radiotherapy is used in curative intent for most patients, in rare cases it can also be used for symptom palliation. 

In parallel with the innovations in radiotherapy applications, an increase in treatment efficiency and a decrease in side effects were observed. Furthermore, radiotherapy induces the treatment efficacy of certain new systemic agents. Combined used of new generation systemic agents and new radiotherapy techniques should increase the survival, even in patients with recurrent or metastatic disease.

Therefore, the unknown parts of radiotherapy and technical innovations about radiotherapy will be explained by the experts of the subject. The special issue provided by ‘European Journal of Gynaecological Oncology’ will enlighten the issues related to radiotherapy for gynecological cancer.

This special issue will include,
· A review section briefly describing the role of radiotherapy in gynecological cancer (cervical cancer, endometrium cancer, vulva and vaginal cancer) and another review section regarding new radiotherapy delivery methods (stereotactic radiotherapy, image-guided brachytherapy, etc.),
· Original articles with gynecological cancer patients treated with radiotherapy and/or surgery and/or systemic therapy,  
· Case reports or interesting images,
· A clinical perspective section, in which guest opinion leader will provide their perspectives for radiotherapy on clinical practice.

Dr. Cem Onal

Guest Editor


Manuscript Submission Information

Manuscripts should be submitted online at https://ejgo.imrpress.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. European Journal of Gynaecological Oncology is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $1250.  Submitted papers should be well formatted and use good English.


Radiotherapy; Gynecological Oncology

Share This Special Issue


Planned Papers

Type: Original Research

Title: The Clinical Outcomes of Ovatian Cancer  in Patients with Brian Metastasis
Author: Dr. Seda Yuksel Simsek

Type: Original Research

Title: Stereotactic body radiotherapy boost in patients with cervical cancer
Author: Melis Gultekin

Type: Original Research

Title: Restaging of cervical cancer patients treated with postoperative radiotherapy according to FIGO 2018 and suggestions for the next staging: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-004)
Author: Senem Alanyalı

Please wait a minute...
For Selected: Toggle Thumbnails
The clinical outcomes of ovarian cancer in patients with brain metastasis
Seda Yuksel Simsek, Ozan Cem Guler, Gülşen Doğan Durdag, Sezin Yüce Sari, Melis Gultekin, Ferah Yildiz, Husnu Celik, Gurcan Erbay, Huseyin Cem Onal
European Journal of Gynaecological Oncology    2021, 42 (5): 881-886.   DOI: 10.31083/j.ejgo4205134
Abstract79)   HTML10)    PDF(pc) (445KB)(34)       Save

Objective: To present the clinical characteristics and treatment outcomes of patients with ovarian cancer with brain metastasis. Methods: This study was designed as a retrospective observational study. Patients' data were obtained from hospital records. Patients who were diagnosed with brain metastatic ovarian cancer in two tertiary referral centers between 2012 and 2020 were included in the study. Results: In total, there were 56 patients diagnosed as having brain metastatic ovarian cancer. The median age was 56 years, 91% of patients were at an advanced stage at initial diagnosis. The median time from the initial diagnosis to brain metastasis was 34.0 months. Sixty-seven percent of patients were determined as having multiple brain metastatic lesions. Whole brain radiotherapy (WBRT), stereotactic radiosurgery (SRS) and combined approach were utilized as primary treatment. The 1 and 2-year survival rates were 38% and 17%, respectively. Patient age and tumor histology were found to be significant prognostic factors that impact the survival in univariate analyses. The 1-year survival of patients aged younger than 55 years was 49.2%, and 28.2% for patients aged over 55 years (p = 0.04). Patients with nonserous histology had significantly longer one year overall survival compared to serous histology (61.4% vs 29.8%) (p = 0.01). Conclusion: The brain is one of the rarest locations for ovarian cancer metastasis. Radiotherapeutic approaches are the mainstay of treatment but survival rates are low. Age and tumor histology were determined as significant parameters that affected survival rates.
Related Articles | Metrics
Comparison of point a based plans with clinical target volume-based three-dimensional plans using dose—volume parameters in small lesion of cervical cancer brachyterapy
Elif Eda Ozer, Melisa Bagci, Esengul Kocak Uzel, Gulsen Pinar Soydemir, Metin Figen, Meltem Kirli Bolukbas
European Journal of Gynaecological Oncology    2021, 42 (5): 936-942.   DOI: 10.31083/j.ejgo4205141
Abstract74)   HTML10)    PDF(pc) (1601KB)(30)       Save

Objective: Intracavitary brachytherapy (ICBT) is the most critical part of cervical cancer treatment which contains a combination of external and intracavitary radiotherapy. We aimed to compare two different plans normalized to point A and the high-risk clinical target volume (HR-CTV) in terms of the target volume and doses for organs at risk (OARs). Methods: Twenty-eight patients with small-residue cervical tumor volume who received CT-based brachytherapy treatment with uterus tandem and double ovoid applicators were included in the study. 3D-ICBT treatment plans normalized to HR-CTV and point A were applied separately to five fractions. We made a total of 280 plans for the two treatment techniques. The patients were given a dose of 5.5 Gy per fraction for a total of 27.5 Gy in 5 fractions. The doses to OAR (rectum, sigmoid, and bladder) and HR-CTV were compared between HR-CTV and point A - based plans. Results: In the brachytherapy treatment planning, the mean doses of HR-CTV D90 and IR-CTV D100 were significantly lower in each fraction and in the total doses when normalized to HR-CTV than when normalized to point A (p < 0.001). D1cc, D2cc, and Dmax values of OAR doses obtained from the brachytherapy treatment planning were significantly lower in each fraction and in the total doses when normalized to HR-CTV than when normalized to point A (p < 0.001). Conclusion: Our findings revealed that, particularly in small-volume HR-CTV after EBRT, plans normalized to HR-CTV can reduce overdose in the target tissue and avoid unnecessary OAR irradiation compared to the plans normalized to point A.
Related Articles | Metrics

Current Issue

  • Volume 42, Issue 5